Key result
Cardiometabolic disorders linked to ~0.9 ng/mL higher soluble endoglin levels vs controls.
Why the study?
Are soluble endoglin (sENG) concentrations elevated in patients with cardiovascular and metabolic disorders compared to controls?
Meta-Analysis (n=2,113)
Are soluble endoglin (sENG) concentrations elevated in patients with cardiovascular and metabolic disorders compared to controls?
Mean Difference: 0.92 (95% CI 0.5–1.34)
p-value: p=< 0.001
Soluble endoglin (sENG) concentrations are significantly elevated in patients with DM1, DM2, and heart failure, suggesting its potential as a novel biomarker for endothelial damage.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rathouska et al. (2026) conducted a meta-analysis in Cardiovascular and metabolic disorders related to endothelial dysfunction (n=2,113). Cardiovascular and metabolic disorders related to endothelial dysfunction vs. Controls was evaluated on Soluble endoglin (sENG) serum/plasma concentrations (MD 0.92 ng/mL, 95% CI 0.50-1.34, p=< 0.001). Patients with cardiovascular and metabolic disorders related to endothelial dysfunction had significantly higher soluble endoglin concentrations than controls (MD 0.92 ng/mL; 95% CI 0.50-1.34; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: